H.C. Wainwright Downgrades Paratek Pharmaceuticals (PRTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts PRTK Hot Sheet
Price: $2.23 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
H.C. Wainwright analyst Ed Arce downgraded Paratek Pharmaceuticals (NASDAQ: PRTK) from Buy to Neutral with a price target of $2.15.
For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.
Shares of Paratek Pharmaceuticals closed at $2.17 yesterday.
You May Also Be Interested In
- TD Cowen Downgrades Artiva Biotherapeutics (ARTV) to Hold
- Needham Downgrades Artiva Biotherapeutics (ARTV) to Hold
- Goldman Sachs Downgrades Xinxiang Richful Lube Additive (300910:CH) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
